← Search & browse all drugs
RESPIRATORY SYSTEM › COUGH AND COLD PREPARATIONS › EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS › Mucolytics
sobrerol
R05CB07
Forms & Strengths
- Oral solution 5% w/v (50 mg/ml)
- Oral tablets 30 mg
- Nebulizable solution 10 mg/ml
Adult Dosing
- 5‑10 mg/kg/day divided TID (max 900 mg/day)
- Oral solution 5‑10 ml three times daily
- Tablets 30 mg every 8 h
Pediatric Dosing
- 2‑4 mg/kg/day divided TID for children >2 yr
- Oral solution 2‑5 ml three times daily
- Not recommended <2 yr
Indications
- Acute bronchitis with productive cough
- Chronic bronchitis and COPD exacerbations
- Bronchiolitis in children
- Upper respiratory tract infections with thick sputum
Mechanism of Action
- Reduces mucus viscosity by disrupting mucopolysaccharide bonds
- Stimulates ciliary beat frequency and mucociliary clearance
- Mild bronchodilatory effect via smooth‑muscle relaxation
Contraindications
- Known hypersensitivity to sobrerol or related terpenes
- Severe bronchospasm or uncontrolled asthma
- Infants <2 years (unless specifically indicated)
Adverse Reactions
- Nausea and vomiting
- Abdominal discomfort
- Taste alteration (bitter)
- Transient rash or urticaria
- Rare bronchospasm
Drug Interactions
- Concurrent mucolytics – additive mucolytic effect
- ACE‑inhibitors – may increase cough, monitor
- Bronchodilators – no significant interaction
- Avoid with strong CYP inhibitors if hepatic metabolism relevant (theoretical)
Curated Content: Needs Vetting Before Put to Clinical Use